Clinical trial
A Phase I, Multicentre, Open-label, Self-control Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
NCT03747653 is registered in ClinicalTrials.gov with Kaifeng Pharmaceutical (Group) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Multicentre, Open-label, Self-control Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- Lead sponsor
- Kaifeng Pharmaceutical (Group) Co., Ltd.
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- March 8, 2019
- Completion date
- May 31, 2020
- Enrollment
- 12 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.